simvastatin has been researched along with Idiopathic Parkinson Disease in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Carroll, C; Chapman, R; Cocking, L; Creanor, S; Foggo, A; Jeffery, A; Jones, B; Stevens, KN; Webb, D; Whone, A; Wilks, J; Zajicek, J | 1 |
| León, CTG; Monroy, A; Montes, S; Morales-Montor, J; Ríos, C; Rubio, C; Rubio-Osornio, M | 1 |
| Brouwers, JF; Kalnytska, O; Martens, GJM; Wieringa, B; Xicoy, H | 1 |
| Ball, S; Carroll, CB; Creanor, S; Eyre, V; Foggo, A; Stevens, KN; Vickery, J; Webb, D; Webber, M; Whone, A; Wyse, R; Zajicek, J | 1 |
| Fan, H; Huang, J; Lai, X; Liu, A; Qiao, L; Shen, M; Wu, J; Yan, J | 1 |
| Bu, WG; Du, RW | 1 |
| Carroll, CB; Wyse, RKH | 1 |
| Deng, C; Gao, H; Huang, XF; Li, J; Liao, J; Liu, X; Qin, B; Tang, B; Wang, Q; Wei, X; Yu, Y | 1 |
| Fang, X; Xu, RS | 1 |
| Lin, KD; Yen, SJ | 1 |
| Brakedal, B; Haugarvoll, K; Tzoulis, C | 1 |
| Cano, J; Hernández-Romero, MC; Machado, A; Santiago, M | 1 |
| Brahmachari, S; Gendelman, HE; Ghosh, A; Matras, J; Pahan, K; Roy, A | 1 |
| Deng, C; Huang, XF; Wang, Q; Wu, A; Xiong, Z; Xu, Y; Yan, J; Yang, Y; Yang, YG; Yenari, MA; Ying, W; Zhang, L; Zhu, C | 1 |
| Bezard, E; Dupouy, S; Galitzky, M; Li, Q; Marquine, L; Meissner, WG; Milhet, A; Nègre-Pagès, L; Ory-Magne, F; Rascol, O; Spampinato, U; Thiolat, ML; Thiollier, T; Tison, F | 1 |
| Kazis, LE; Lee, A; Lee, TA; Li, NC; Wang, SW; Wolozin, B | 1 |
4 trial(s) available for simvastatin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.
Topics: Disease Progression; Double-Blind Method; Female; Humans; Male; Parkinson Disease; Simvastatin; State Medicine; Treatment Outcome | 2022 |
Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
Topics: Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Interviews as Topic; Male; Middle Aged; Neurologic Examination; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Randomized Controlled Trials as Topic; Simvastatin | 2019 |
Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mental Status Schedule; Neurodegenerative Diseases; Neuropsychological Tests; Parkinson Disease; Simvastatin | 2017 |
Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
Topics: Adult; Aged; Animals; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Macaca; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Simvastatin | 2013 |
12 other study(ies) available for simvastatin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Repurposing Simvastatin in Parkinson's Disease Model: Protection Is throughout Modulation of the Neuro-Inflammatory Response in the
Topics: 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Parkinson Disease; Proteomics; Rats; Simvastatin; Substantia Nigra | 2023 |
Lipid Analysis of the 6-Hydroxydopamine-Treated SH-SY5Y Cell Model for Parkinson's Disease.
Topics: Cell Line, Tumor; Cholesterol; Humans; Lipidomics; Lipids; Models, Biological; Oxidopamine; Parkinson Disease; Simvastatin | 2020 |
Simvastatin Improves Behavioral Disorders and Hippocampal Inflammatory Reaction by NMDA-Mediated Anti-inflammatory Function in MPTP-Treated Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Dopaminergic Neurons; Hippocampus; Inflammation; Mice, Inbred C57BL; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Simvastatin | 2020 |
Simvastatin Prevents Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease via Inhibition of A1 Reactive Astrocytes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Disease Models, Animal; Dopaminergic Neurons; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neuroprotective Agents; Parkinson Disease; Simvastatin | 2021 |
Simvastatin reverses the downregulation of M1/4 receptor binding in 6-hydroxydopamine-induced parkinsonian rats: the association with improvements in long-term memory.
Topics: Animals; Brain; Disease Models, Animal; Down-Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maze Learning; Memory, Long-Term; Muscarinic Antagonists; Oxidopamine; Parkinson Disease; Pirenzepine; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Simvastatin; Sympatholytics; Tritium | 2014 |
Protective effect of simvastatin on impaired intestine tight junction protein ZO-1 in a mouse model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Parkinson Disease; Simvastatin; Zonula Occludens-1 Protein | 2015 |
Reply.
Topics: Humans; Parkinson Disease; Simvastatin | 2017 |
Simvastatin is associated with decreased risk of Parkinson disease.
Topics: Animals; Diabetes Mellitus; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Parkinson Disease; Simvastatin | 2017 |
Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+ does not.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Lipopolysaccharides; Male; Microdialysis; Nerve Endings; Neuroprotective Agents; Parkinson Disease; Perfusion; Rats; Rats, Wistar; Simvastatin | 2009 |
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Cell Survival; Disease Models, Animal; Dopamine; Humans; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neuroglia; Neurons; Neuroprotective Agents; Neurotransmitter Agents; NF-kappa B; Parkinson Disease; Parkinsonian Disorders; Pravastatin; Proto-Oncogene Proteins p21(ras); Simvastatin; Substantia Nigra | 2009 |
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses.
Topics: Animals; Anti-Inflammatory Agents; Anxiety; Apoptosis; Autoradiography; Cell Survival; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Glutamic Acid; Immunohistochemistry; L-Lactate Dehydrogenase; Male; Matrix Metalloproteinase 9; Nerve Degeneration; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Simvastatin; Substantia Nigra; Tritium; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2011 |
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases as Topic; Dementia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Parkinson Disease; Proportional Hazards Models; Pyrroles; Simvastatin; United States; Veterans | 2007 |